Canaccord Genuity Initiates Mast Therapeutics With Buy

by Monica Gerson, Benzinga Staff Writer

November 17, 2014 8:40 AM | 12 seconds read | Make a Comment

Analysts at Canaccord Genuity initiated coverage on shares of Mast Therapeutics

MSTX

with a Buy rating. The target price for Mast Therapeutics is set to $3. Mast Therapeutics' shares jumped 11.11% to $0.50 in pre-market trading.

Posted In: Initiation Analyst Ratings Canaccord Genuity

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.